NASDAQ:FATE - Fate Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $111.18
  • Forecasted Upside: 35.75 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
▲ +1.67 (2.08%)

This chart shows the closing price for FATE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fate Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FATE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FATE

Analyst Price Target is $111.18
▲ +35.75% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Fate Therapeutics in the last 3 months. The average price target is $111.18, with a high forecast of $145.00 and a low forecast of $76.00. The average price target represents a 35.75% upside from the last price of $81.90.

This chart shows the closing price for FATE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 14 contributing investment analysts is to buy stock in Fate Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/7/2021HC WainwrightUpgradeNeutral ➝ Buy$120.00High
5/14/2021WedbushDowngradeOutperform ➝ NeutralMedium
5/7/2021WedbushUpgradeNeutral ➝ Outperform$88.00Low
4/26/2021Jefferies Financial GroupInitiated CoverageBuy$145.00Low
3/12/2021SVB LeerinkBoost Price TargetOutperform$58.00 ➝ $121.00Medium
3/4/2021WedbushReiterated RatingOutperform ➝ NeutralHigh
3/4/2021Wells Fargo & CompanyBoost Price TargetOverweight$84.00 ➝ $130.00N/A
2/26/2021TruistBoost Price Target$85.00 ➝ $135.00Medium
2/26/2021Bank of AmericaInitiated CoverageBuy$115.00High
2/26/2021WedbushDowngradeOutperform ➝ NeutralHigh
2/25/2021Roth CapitalBoost Price Target$30.00 ➝ $90.00High
2/25/2021Cantor FitzgeraldBoost Price TargetOverweight$86.00 ➝ $98.00High
2/25/2021MizuhoBoost Price TargetBuy$88.00 ➝ $109.00High
2/17/2021Piper SandlerBoost Price TargetOverweight$99.00 ➝ $116.00Low
2/11/2021CitigroupDowngradeBuy ➝ NeutralLow
1/27/2021HC WainwrightReiterated RatingNeutral$108.00Medium
1/25/2021BMO Capital MarketsBoost Price TargetMarket Perform$57.00 ➝ $88.00Medium
1/19/2021OppenheimerReiterated RatingOutperform$70.00 ➝ $135.00High
1/15/2021BarclaysBoost Price TargetPositive ➝ Overweight$110.00 ➝ $130.00High
12/21/2020Stifel NicolausBoost Price TargetBuy$79.00 ➝ $118.00High
12/17/2020BarclaysBoost Price TargetOverweight$80.00 ➝ $110.00Low
12/8/2020MizuhoBoost Price TargetBuy$40.00 ➝ $88.00High
12/7/2020BMO Capital MarketsBoost Price TargetMarket Perform$43.00 ➝ $57.00High
12/7/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$63.00 ➝ $76.00High
12/7/2020Wells Fargo & CompanyBoost Price TargetOverweight$61.00 ➝ $84.00High
12/7/2020WedbushBoost Price TargetOutperform$55.00 ➝ $88.00High
12/7/2020Smith Barney CitigroupBoost Price Target$63.00 ➝ $76.00High
12/7/2020Piper SandlerBoost Price TargetOverweight$71.00 ➝ $99.00High
12/7/2020OppenheimerBoost Price TargetOutperform$60.00 ➝ $70.00High
12/7/2020SVB LeerinkBoost Price TargetOutperform$34.00 ➝ $58.00High
12/2/2020BarclaysBoost Price TargetOverweight$60.00 ➝ $70.00Low
11/24/2020TruistBoost Price Target$40.00 ➝ $65.00Low
11/9/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$40.00 ➝ $63.00Medium
11/9/2020Smith Barney CitigroupBoost Price Target$40.00 ➝ $63.00Low
11/8/2020OppenheimerBoost Price TargetOutperform$40.00 ➝ $60.00High
11/6/2020Piper SandlerBoost Price TargetOverweight$59.00 ➝ $71.00Low
11/6/2020Wells Fargo & CompanyBoost Price TargetOverweight$38.00 ➝ $61.00High
11/6/2020BMO Capital MarketsBoost Price TargetMarket Perform$29.00 ➝ $43.00High
10/15/2020BarclaysBoost Price TargetOverweight$40.00 ➝ $60.00High
8/13/2020Cantor FitzgeraldBoost Price TargetOverweight$32.00 ➝ $40.00Low
8/6/2020HC WainwrightReiterated RatingBuy$42.00Medium
8/6/2020OppenheimerReiterated RatingBuy$40.00High
6/9/2020OppenheimerInitiated CoverageBuy$34.00 ➝ $40.00Low
6/9/2020Piper SandlerLower Price Target$63.00 ➝ $59.00Low
5/13/2020HC WainwrightInitiated CoverageBuy$42.00High
5/12/2020BMO Capital MarketsBoost Price TargetMarket Perform$28.00 ➝ $29.00High
4/6/2020OppenheimerLower Price TargetOutperform$36.00 ➝ $34.00Low
4/3/2020Piper SandlerBoost Price TargetHigh
4/3/2020WedbushBoost Price TargetOutperform$38.00 ➝ $41.00High
4/3/2020MizuhoReiterated RatingBuy$40.00High
3/4/2020CitigroupBoost Price TargetBuy$26.00 ➝ $41.00High
3/4/2020BarclaysInitiated CoverageOverweight$40.00High
3/3/2020BMO Capital MarketsBoost Price Target$22.00 ➝ $28.00High
3/3/2020Roth CapitalBoost Price Target$20.00 ➝ $30.00High
3/3/2020BTIG ResearchBoost Price TargetBuy$27.00 ➝ $42.00High
3/3/2020Piper SandlerBoost Price TargetOverweight$28.00 ➝ $57.00High
3/3/2020GuggenheimBoost Price TargetBuy$25.00 ➝ $41.00High
3/3/2020OppenheimerBoost Price TargetOutperform$27.00 ➝ $36.00High
2/26/2020MizuhoBoost Price TargetBuy$33.00 ➝ $40.00High
2/14/2020WedbushBoost Price TargetOutperform$29.00 ➝ $33.00Medium
2/12/2020Wells Fargo & CompanyReiterated RatingOverweight$24.00 ➝ $34.00High
1/9/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$22.00High
12/30/2019MizuhoBoost Price TargetBuy ➝ Buy$27.00 ➝ $33.00High
12/9/2019OppenheimerReiterated RatingBuy$27.00High
12/9/2019BMO Capital MarketsLower Price TargetOutperform$26.00 ➝ $22.00High
12/9/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$24.00High
11/12/2019SunTrust BanksInitiated CoverageBuy$25.00Low
11/6/2019Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$24.00 ➝ $16.00High
9/30/2019Stifel NicolausInitiated CoverageBuy$27.00High
9/16/2019Piper Jaffray CompaniesLower Price TargetOverweight$30.00 ➝ $28.00Low
9/4/2019MizuhoReiterated RatingBuy$27.00High
8/9/2019BTIG ResearchInitiated CoverageBuy ➝ Buy$27.00High
8/7/2019BMO Capital MarketsSet Price TargetBuy$27.00High
8/7/2019WedbushBoost Price TargetOutperform$21.00 ➝ $26.00High
7/22/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$32.00 ➝ $32.00High
7/12/2019CIBCInitiated CoverageOutperform ➝ Outperform$27.00High
7/12/2019OppenheimerInitiated CoverageOutperform$27.00 ➝ $27.00High
6/27/2019Piper Jaffray CompaniesBoost Price TargetOverweight ➝ Top Pick$23.00 ➝ $30.00High
6/12/2019MizuhoInitiated CoverageBuy ➝ Buy$27.00High
6/7/2019Roth CapitalInitiated CoverageNeutral ➝ Neutral$20.00 ➝ $20.00Medium
5/30/2019GuggenheimInitiated CoverageBuy$25.00High
5/24/2019CitigroupReiterated RatingBuy ➝ Buy$20.00 ➝ $26.00Low
3/28/2019SVB LeerinkInitiated CoverageOutperform$20.00Medium
3/6/2019Wells Fargo & CompanyBoost Price TargetOutperform$18.00 ➝ $24.00High
2/11/2019WedbushBoost Price TargetOutperform ➝ Outperform$19.00 ➝ $21.00Low
1/3/2019StephensDowngradeOverweight ➝ EqualMedium
11/5/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$17.00Low
9/25/2018Piper Jaffray CompaniesReiterated RatingOverweight$23.00High
9/18/2018Piper Jaffray CompaniesReiterated RatingOverweight$25.00High
8/7/2018WedbushReiterated RatingOutperform$19.00High
8/7/2018HC WainwrightReiterated RatingHold$12.00High
8/1/2018CitigroupInitiated CoverageBuy$20.00High
3/29/2018WedbushReiterated RatingOutperform$19.00Low
3/20/2018HC WainwrightReiterated RatingHold$12.00Medium
3/6/2018UBS GroupDowngradeOutperform ➝ Market PerformHigh
3/6/2018WedbushReiterated RatingOutperform ➝ Outperform$19.00 ➝ $10.00High
3/6/2018HC WainwrightDowngradeBuy ➝ Neutral$12.00High
3/6/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$7.00 ➝ $20.00High
3/6/2018Wells Fargo & CompanyReiterated RatingOutperform$10.00 ➝ $19.00High
3/6/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Top Pick$20.00High
1/18/2018WedbushReiterated RatingOutperform$10.00 ➝ $7.00Medium
12/18/2017WedbushReiterated RatingOutperform$7.00Low
12/18/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$10.00Medium
12/13/2017HC WainwrightReiterated RatingBuy$7.00High
12/12/2017Raymond JamesReiterated RatingBuyMedium
11/10/2017HC WainwrightReiterated RatingBuy$7.00N/A
11/2/2017HC WainwrightReiterated RatingBuyN/A
11/2/2017BMO Capital MarketsReiterated RatingBuy$7.00N/A
10/12/2017HC WainwrightReiterated RatingBuy ➝ Buy$7.00N/A
9/8/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$7.00Medium
5/16/2017WedbushReiterated RatingOutperform$7.00High
3/20/2017HC WainwrightLower Price TargetBuy$8.00 ➝ $6.00Low
3/18/2017Roth CapitalSet Price TargetBuy$8.00Low
3/17/2017WedbushReiterated RatingOutperform$7.00Medium
3/17/2017BMO Capital MarketsBoost Price TargetBuy$7.00Medium
2/28/2017WedbushReiterated RatingOutperform$7.00N/A
12/6/2016BMO Capital MarketsReiterated RatingOutperform$4.00N/A
11/8/2016WedbushLower Price TargetOutperform$8.00 ➝ $7.00N/A
9/22/2016Roth CapitalInitiated CoverageBuy$8.00N/A
8/9/2016HC WainwrightReiterated RatingBuyN/A
8/8/2016BMO Capital MarketsSet Price TargetBuy$4.00N/A
7/28/2016HC WainwrightInitiated CoverageBuy$9.00N/A
(Data available from 6/22/2016 forward)
Fate Therapeutics logo
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors, as well as ProTmune for the treatment of hematologic malignancies and rare genetic disorders. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $81.90
Low: $78.48
High: $82.17

50 Day Range

MA: $80.09
Low: $67.25
High: $92.52

52 Week Range

Now: $81.90
Low: $29.37
High: $121.16


977,205 shs

Average Volume

1,049,797 shs

Market Capitalization

$7.70 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Fate Therapeutics?

The following equities research analysts have issued research reports on Fate Therapeutics in the last year: Bank of America Co., Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, HC Wainwright, Jefferies Financial Group Inc., Mizuho, Oppenheimer Holdings Inc., Piper Sandler, Roth Capital, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, Truist, Wedbush, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for FATE.

What is the current price target for Fate Therapeutics?

17 Wall Street analysts have set twelve-month price targets for Fate Therapeutics in the last year. Their average twelve-month price target is $111.18, suggesting a possible upside of 35.7%. Jefferies Financial Group Inc. has the highest price target set, predicting FATE will reach $145.00 in the next twelve months. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell has the lowest price target set, forecasting a price of $76.00 for Fate Therapeutics in the next year.
View the latest price targets for FATE.

What is the current consensus analyst rating for Fate Therapeutics?

Fate Therapeutics currently has 3 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FATE will outperform the market and that investors should add to their positions of Fate Therapeutics.
View the latest ratings for FATE.

What other companies compete with Fate Therapeutics?

How do I contact Fate Therapeutics' investor relations team?

Fate Therapeutics' physical mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company's listed phone number is 858-875-1800 and its investor relations email address is [email protected] The official website for Fate Therapeutics is